

Cosentyx Rheum - HCP resources - HCP

[Prescribing information](#)

Image



Image



Cosentyx® (secukinumab): HCP resources

Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate conventional

therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years or older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.¹

[Full indication for Cosentyx can be found here.](#)

[Cosentyx Summary of Product Characteristics \(SmPC\) can be found here.](#)

Explore our range of educational resources designed for you and your patients

These promotional resources are developed and funded by Novartis UK for healthcare professionals to support their education and the initiation and treatment of patients throughout their Cosentyx journey. Navigate the sections below to find educational resources for download and use by healthcare professionals only, as well as resources that you can share with your patients.

Please do not share links to this page with patients.

This section of the website is intended for HCPs only, and contains promotional material. If you wish to direct patients to the patient resources, use the link below:

pro.novartis.com/uk-en/public/medicines/rheumatology/cosentyx/patient-resources

-
- [Resources for HCPs](#)

- [Video resources for HCPs](#)

- [Resources for patients](#)

Image

Promotional material produced and funded by Novartis for UK healthcare professionals only. Prescribing information can be found [here](#).



Confidence to prescribe Cosentyx® (secukinumab) for your eligible patients

Chosen for 8 years by clinicians like you^{1,2}

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Indications:

Treatment of: **moderate to severe plaque psoriasis in adults**, children and adolescents from the age of 6 years who are candidates for systemic therapy; **active moderate to severe hidradenitis suppurativa (acne inversa) in adults** with an inadequate response to conventional systemic HS therapy; **active psoriatic arthritis in adults** (alone or in combination with methotrexate) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; **active ankylosing spondylitis in adults** who have responded inadequately to conventional therapy; **active non-radiographic axial spondyloarthritis with objective signs of inflammation** as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; **active enthesitis-related arthritis** and **juvenile psoriatic arthritis in patients 6 years and older** (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.¹

Please refer to the Cosentyx Summary of Product Characteristics (SmPC) for further information about the clinical indications.¹

UK | February 2025 | FA-11323563



Confidence to prescribe Cosentyx

PDF

[Download](#)

Image

Promotional material produced and funded by
Novartis for UK healthcare professionals only.

Prescribing information can be found [here](#).



1,000,000
patients treated
globally and
counting, across
indications⁸

Proven efficacy in skin and joints with Cosentyx® (secukinumab)¹⁻⁷

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at
www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Indications:

Treatment of: **moderate to severe plaque psoriasis** in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; **active psoriatic arthritis** in adults (alone or in combination with methotrexate) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; **active ankylosing spondylitis** in adults who have responded inadequately to conventional therapy; **active non-radiographic axial spondyloarthritis** with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; **active enthesitis-related arthritis and juvenile psoriatic arthritis** in patients 6 years and older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; **active moderate to severe hidradenitis suppurativa (acne inversa)** in adults with an inadequate response to conventional systemic HS therapy.⁹

Please refer to the Cosentyx Summary of Product Characteristics (SmPC) for further information about the clinical indications.⁹

Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for dosing in special populations.⁹

UK | February 2025 | FA-11323632



Efficacy with Cosentyx

PDF

[Download](#)

- [Resources for HCPs](#)

- [Video resources for HCPs](#)

- [Resources for patients](#)



Video

5 mins 56 secs

SensoReady® 150 mg injection video

Video - 15 Jul 2024

5 mins 56 secs

SensoReady® 150 mg injection video

A short video showing you how to prepare and inject Cosentyx with the SensoReady® pen.

[See more details](#)

Hide details



Video

UnoReady® 300 mg injection video

Video - 18 Feb 2025

UnoReady® 300 mg injection video

A short video showing you how to prepare and inject Cosentyx with the UnoReady® 300mg pen.

[See more details](#)

Hide details

- [Resources for HCPs](#)

- [Video resources for HCPs](#)

- [Resources for patients](#)

Image



PsA patient leaflet

PDF

[Download](#)

Image



AS patient leaflet

PDF

[Download](#)

Image



ERA patient leaflet

PDF

[Download](#)

Image



JPsA patient leaflet

PDF

[Download](#)

Image

Please read this leaflet if you have been prescribed Cosentyx® 300 mg

This is a different pen and so will affect your administration of Cosentyx®

Cosentyx® 300 mg injection secukinumab

Always use Cosentyx® exactly as your doctor or nurse has described. It is important not to try to inject yourself until you have been trained by your doctor, nurse, or pharmacist – check with them if you are unsure

This leaflet is intended for patients who have been prescribed Cosentyx. It has been produced and funded by Novartis Pharmaceuticals UK Ltd.
UK, 1 April 2023, 1108808
© 2023 Novartis Pharmaceuticals UK Limited

NOVARTIS



Cosentyx® secukinumab

UnoReady 300 mg alert leaflet

PDF

[Download](#)

Image



Cosentyx patient dosing schedule for Psoriatic Arthritis

Keep track of your Cosentyx treatment using the dosing schedule below. Your healthcare professional should have already entered your planned injection dates.

You can tick the clickable circles after administering Cosentyx[®], or alternatively print the document to keep track by hand.

*Please note that the clickable function may not work on some devices.

Tick the circle when you've had your treatment on the planned date.

Your healthcare professional has already entered your planned injection dates here.

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

Week 0 1 2 3 4

Month 1

This is your last weekly dose, the injections will now be monthly.

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

Month 7 Month 6 Month 5 Month 4 Month 3 Month 2

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

Month 8 Month 9 Month 10 Month 11 Month 12

Treatment continues once monthly. Consult your healthcare professional for further planned injection dates.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. Side effects may also be reported to Novartis on 01276 660370 or via medinfo.uk@novartis.com. By reporting side effects you can help provide more information on the safety of this medicine.

This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd. 262776 Date of preparation: December 2022

Digital dosing schedule - PsA

PDF

[Download](#)

Image

Cosentyx patient dosing schedule for axSpA (ankylosing spondylitis or non-radiographic axial spondyloarthritis)

Name:

Prescribed dose:

Keep track of your Cosentyx treatment using the dosing schedule below. Your healthcare professional should have already entered your planned injection dates.

You can tick the clickable circles after administering Cosentyx*, or alternatively print the document to keep track by hand.

*Please note that the clickable function may not work on some devices.

Tick the circle when you've had your treatment on the planned date.

Your healthcare professional has already entered your planned injection dates here.



This is your last weekly dose; the injections will now be monthly.



Treatment continues once monthly. Consult your healthcare professional for further planned injection dates.

Reporting of side effects

If you get any side effects, tell your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.fda.gov/medwatch or medwatch@novartis.com.

By reporting side effects you can help provide more information on the safety of this medicine.

This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd.
220777 Date of preparation: December 2022

Digital dosing schedule - axSpA

PDF

[Download](#)

Image

Cosentyx (secukinumab) 2 weekly dosing schedule for adult patients with psoriatic arthritis and concomitant plaque psoriasis with a body weight of 90 kg or higher


Name:		Prescribed dose:	
-------	--	------------------	--

Keep track of your Casertyx treatment using the dosing schedule below. Your healthcare professional should have already entered your planned infusion dates.

You can click the clickable circles after administering Consent/x*, or alternatively print the document to keep track by hand.

*Please note that the clickable function may not work on some devices.

Tick the circle
when you've had
your treatment on
the planned date



Reporting of side-effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard

This resource is only intended for adult patients in the UK with plaque psoriasis with a body weight of 50 kg or more. Not for further distribution.

This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd
UK 1 March 2010 1-789544

Digital dosing schedule - PsA Q2W

PDF

Download

Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for full product information and administration, including dosing in special populations, before prescribing.¹ Cosentyx has not been studied in patients with renal impairment or hepatic impairment. No dose recommendations can be made.

Therapeutic Indications¹

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to

severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.¹

AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; ERA, enthesitis-related arthritis; GB, Great Britain; HCP, healthcare professional; HS, hidradenitis suppurativa; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NI, Northern Ireland; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC, Summary of Product Characteristics.

Reference

1. Cosentyx® (secukinumab) Summary of Product Characteristics

UK | March 2025 | FA-11357098-1

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

<https://www.pro.novartis.com/uk-en/medicines/rheumatology/cosentyx/resources>